Altimmune is trading 5.02% higher at $3.25, with biotech-sector strength the clearest explanation after no new company-specific announcement was identified for September 2, 2026.
- The XBI sector ETF is up 2.75%, supported by patent-related gains and continued positive industry momentum.
- Major equity indexes are only modestly higher; earlier clinical and earnings updates remain supportive background, not a fresh catalyst.